-
Article from Cloud-based Medicine Studio | A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated
(attachments: the first list and the national reimbursement drug list)January 31, 2023 -
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in china
January 18, 2023 -
CANbridge Congratulates Apogenix on First Patient Dosed in Asunercept (CAN008) Phase 3 Trial for the Treatment of COVID-19
-CANbridge holds exclusive rights for the development of CAN008 for any indication in Greater China
-CAN008 currently in Phase 2 trial for the treatment of glioblastoma multiforme in China
January 5, 2023 -
CANbridge Consolidates Gene Therapy Portfolio
-Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School
-Completes Technology Transfer of Two Gene Therapies for Lysomal Storage Diseases
January 4, 2023 -
CANbridge Congratulates Mirum on EU Marketing Approval for Maralixibat/LIVMARLI® to Treat Cholestatic Pruritis in Rare Liver Disease, Alagille Syndrome
-Together with recent positive topline Phase 3 data in progressive familial intrahepatic cholestasis (PFIC), approval underscores maralixibat potential as promising new rare liver disease treatment
-CANbridge holds exclusive Greater China license to maralixibat (CAN108) in liver diseases, China part of global trial ongoing in biliary atresia (BA)
December 20, 2022 -
CANbridge Pharmaceuticals Announces Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis
November 16, 2022 -
Article from PhIRDA|Bi Jingquan: To encourage the R&D of drugs for rare diseases, we need to study and formulate special policies that conform to the characteristics of rare diseases
November 1, 2022 -
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease
- Congratulates Mirum on Positive Topline Phase 3 Data in progressive familial intrahepatic cholestasis (PFIC)
- CANbridge holds exclusive Greater China license to maralixibat (CAN108) in liver diseases, China trial ongoing in biliary atresia (BA)
October, 27, 2022 -
CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress
October, 13, 2022
Media Reports
Press Release